Addressing Manufacturing and Characterization Challenges and Opportunities with Novel AAV Capsids

Adeno-associated viruses (AAVs) play a critical role in advancing gene therapies due to their safety profile and ability to target diverse tissues. As research evolves, novel AAV capsids are being developed to enhance transduction efficiency, minimize immune responses, and improve precision in tissue targeting. These innovations hold significant promise for expanding treatment possibilities across a wider range of disorders.

However, the introduction of novel capsid designs also brings new challenges. Manufacturing processes become more complex, requiring refined strategies to ensure consistency, scalability, and quality. At the same time, existing analytical methods—originally designed for wild-type capsids—must be reevaluated and optimized to remain effective for newer variants.

See highlights of practical approaches to overcoming these obstacles, including advancements in manufacturing techniques, updated analytical testing strategies, and key regulatory considerations necessary to support the successful development and commercialization of next-generation gene therapies.